Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
11.16
+0.20 (1.82%)
Jun 5, 2025, 4:00 PM - Market closed
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for Syndax Pharmaceuticals stock ranges from a low of $17 to a high of $51. The average analyst price target of $35.91 forecasts a 221.77% increase in the stock price over the next year.
Price Target: $35.91 (+221.77%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 6, 2025.
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 8 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Hold Maintains $16 → $17 | Hold | Maintains | $16 → $17 | +52.33% | May 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +186.74% | May 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $39 → $41 | Buy | Maintains | $39 → $41 | +267.38% | Mar 20, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $35 → $39 | Buy | Maintains | $35 → $39 | +249.46% | Mar 4, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $45 → $42 | Strong Buy | Maintains | $45 → $42 | +276.34% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
124.74M
from 23.68M
Increased by 426.77%
Revenue Next Year
247.37M
from 124.74M
Increased by 98.31%
EPS This Year
-3.75
from -3.72
EPS Next Year
-2.69
from -3.75
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 161.9M | 305.0M | 491.6M | ||
| Avg | 124.7M | 247.4M | 370.4M | ||
| Low | 81.3M | 174.4M | 239.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 583.9% | 144.5% | 98.7% | ||
| Avg | 426.8% | 98.3% | 49.7% | ||
| Low | 243.5% | 39.8% | -3.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.76 | -0.92 | -0.89 | ||
| Avg | -3.75 | -2.69 | -1.63 | ||
| Low | -4.07 | -3.25 | -2.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.